LinkGevity Secures Place in Prestigious SPACE-H Accelerator Program
Groundbreaking Anti-Necrotic Technology Supporting Space Missions and Space Health
London, UK, 11 September – LinkGevity, an AI-driven drug discovery company focused on longevity and age-related disease, announces its selection for the highly competitive SPACE-H Accelerator program, powered by Starburst in collaboration with NASA’s Human Research Program (NASA HRP), the Translational Research Institute for Space Health (TRISH), and Microsoft Federal (Microsoft). The program, in its inaugural year, is dedicated to advancing innovative solutions for human health and performance in space. LinkGevity has been selected as its research has uncovered a first in class Anti-Necrotic technology with significant potential to minimize the health and performance risks in human spaceflight.
